Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency seeks more clinical data on canakinumab in refractory patients after an advisory committee meeting that focused on the drug's potential risks.